## Roy Mano

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9026738/publications.pdf

Version: 2024-02-01

		331670	315739
103	1,754 citations	21	38
papers	citations	h-index	g-index
103	103	103	2853
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Anterior and apical samplings during transperineal image-guided prostate biopsy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 5.e15-5.e21.	1.6	2
2	Flexible Cystoscopy in the Setting of Macroscopic Hematuria: Do the Findings Justify Its Use?. Urologia Internationalis, 2022, 106, 147-153.	1.3	1
3	Introducing in clinical practice a new laser suction handpiece for percutaneous nephrolithotomy. Urologia, 2022, 89, 570-574.	0.7	2
4	The association between modifiable perioperative parameters and renal function after nephrectomy. BJU International, 2022, 129, 380-386.	2.5	2
5	Asymptomatic bacteriuria and antibiotic resistance profile in children with neurogenic bladder who require clean intermittent catheterization. Spinal Cord, 2022, 60, 256-260.	1.9	5
6	Testicular microlithiasis defines a subgroup of azoospermic men with low rates of sperm retrieval. International Journal of Urology, 2022, 29, 65-68.	1.0	0
7	Concomitant Repair of Meatal Stenosis and Urethral Fistula Does Not Increase the Risk of Fistula Recurrence Post Hypospadias Surgery. Urology, 2022, 160, 187-190.	1.0	1
8	Parental Regret Following Decision to Revise Circumcision. Frontiers in Pediatrics, 2022, 10, 855893.	1.9	3
9	Impact of COVIDâ€19 pandemic on patients with obstructing urinary stones complicated by infection. BJUI Compass, 2022, 3, 298-303.	1.3	2
10	Querying the significance of patient position during computerized tomography on the reliability of pre-percutaneous nephrolithotomy planning. World Journal of Urology, 2022, , $1.$	2.2	1
11	Association between early change in neutrophilâ€toâ€lymphocyte ratio after radical cystectomy and treatment outcomes. BJU International, 2022, 130, 470-477.	2.5	4
12	Systemic immunological determinants of oncological outcomes after surgery for localized renal cell carcinoma. Clinical Genitourinary Cancer, 2022, , .	1.9	0
13	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. Bladder Cancer, 2022, 8, 291-301.	0.4	1
14	The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findingsâ€"Implications for the COVID-19 era. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 73.e1-73.e8.	1.6	5
15	Long-Term Follow-Up of Yearly Replaced Double Internal Stents for Extrinsic Malignant Ureteral Obstruction. Journal of Endourology, 2021, 35, 71-76.	2.1	9
16	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. European Urology, 2021, 79, 468-477.	1.9	35
17	Identifying Clear Cell Renal Cell Carcinoma Coexpression Networks Associated with Opioid Signaling and Survival. Cancer Research, 2021, 81, 1101-1110.	0.9	10
18	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. European Urology Focus, 2021, 7, 381-389.	3.1	28

#	Article	IF	CITATIONS
19	Novel ultrasound-based volume estimation of prostatic benign enlargement to improve decision-making on surgical approach. Therapeutic Advances in Urology, 2021, 13, 175628722199330.	2.0	4
20	The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. EJNMMI Research, 2021, 11, 3.	2.5	16
21	Radical cystectomy and perioperative chemotherapy in octogenarians with bladder cancer. Canadian Urological Association Journal, 2021, 15, E465-E470.	0.6	2
22	Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection. Prostate Cancer and Prostatic Diseases, 2021, 24, 910-916.	3.9	7
23	A qualitative framework of non-selection factors for cytoreductive nephrectomy. World Journal of Urology, 2021, 39, 3359-3365.	2.2	3
24	Questioning the utility of round spermatid injections in men with nonâ€obstructive azoospermia. Andrology, 2021, 9, 1145-1150.	3.5	2
25	Dorsal penile curvature and megameatus intact prepuce hypospadias: A common association in a rare variant of hypospadias. Journal of Pediatric Urology, 2021, 17, 517.e1-517.e4.	1.1	4
26	Resource-efficient pooled sequencing expands translational impact in solid tumors. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 18-23.	0.1	1
27	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer, 2021, 127, 3946-3956.	4.1	12
28	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma $\hat{a} \in \text{``An exploratory analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 791.e17-791.e24.}$	1.6	3
29	Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. Nutrients, 2021, 13, 4295.	4.1	11
30	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. World Journal of Urology, 2020, 38, 1959-1968.	2.2	22
31	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. Urology, 2020, 136, 169-175.	1.0	9
32	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncology, The, 2020, 21, 283-293.	10.7	121
33	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology, 2020, 3, 47-56.	5.4	20
34	Preoperative nomogram predicting 12-year probability of metastatic renal cancer – evaluation in a contemporary cohort. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 853.e1-853.e7.	1.6	6
35	Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. British Journal of Anaesthesia, 2020, 125, e402-e404.	3.4	15
36	Predictors of long-term renal function after kidney surgery for patients with preoperative chronic kidney disease. Canadian Urological Association Journal, 2020, 15, E103-E109.	0.6	0

#	Article	IF	CITATIONS
37	An evaluation of the role of tumor load in cytoreductive nephrectomy. Canadian Urological Association Journal, 2020, 14, E625-E630.	0.6	1
38	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Scientific Reports, 2020, 10, 701.	3.3	21
39	Primary urethral cancer: treatment patterns and associated outcomes. BJU International, 2020, 126, 359-366.	2.5	7
40	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640.	7.0	30
41	Editorial Comment. Journal of Urology, 2020, 204, 713-713.	0.4	0
42	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 916-923.	1.6	8
43	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 811.e9-811.e16.	1.6	6
44	The evolving role of cytoreductive nephrectomy. Current Opinion in Urology, 2019, 29, 531-539.	1.8	1
45	Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 209-218.	1.6	28
46	Are the long-term outcomes of percutaneous ablation for clinical stage T1 renal tumors similar to those of partial nephrectomy?. Annals of Translational Medicine, 2019, 7, S370-S370.	1.7	0
47	Malignant Abnormalities in Male <i>BRCA</i> Mutation Carriers. JAMA Oncology, 2018, 4, 872.	7.1	17
48	Urinary Tract Infections After Urinary Diversion—Different Occurrence Patterns in Patients With Ileal Conduit and Orthotopic Neobladder. Urology, 2018, 116, 87-92.	1.0	18
49	Transplant Kidney Retrograde Ureteral Stent Placement and Exchange: Overcoming the Challenge. Urology, 2018, 111, 220-224.	1.0	10
50	Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-GuÃ@rin immunotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 531.e9-531.e17.	1.6	14
51	Reply by the Authors. Urology, 2018, 115, 193.	1.0	0
52	Missed Torsion of the Spermatic Cord: A Common yet Underreported Event. Urology, 2017, 102, 202-206.	1.0	15
53	Clinical Implications of Stent Culture in Patients with Indwelling Ureteral Stents Prior to Ureteroscopy. Journal of Urology, 2017, 198, 116-121.	0.4	19
54	Lower Urinary Tract Symptoms and Benign Prostate Hyperplasia Features Among Male BRCA Mutation Carriers. Urology, 2017, 108, 71-75.	1.0	1

#	Article	IF	Citations
55	Post-ritual Circumcision Bleedingâ€"Characteristics and Treatment Outcome. Urology, 2017, 105, 157-162.	1.0	8
56	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. Journal of Urology, 2017, 197, 391-397.	0.4	10
57	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal <i>SDHB</i> Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. JCO Precision Oncology, 2017, 1, 1-14.	3.0	9
58	Is there a difference in testosterone levels and its regulators in men carrying BRCA mutations?. Oncotarget, 2017, 8, 103843-103850.	1.8	3
59	Validation and genomic interrogation of the <scp><i>MET</i></scp> variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer, 2016, 122, 402-410.	4.1	18
60	MP71-14 ANALYSIS OF THE MUTATIONAL LANDSCAPE OF SARCOMATOID CLEAR CELL RENAL CELL CARCINOMA COMPARED TO CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2016, 195, .	0.4	1
61	Surgical Treatment of Tumors Involving Kidneys With Fusion Anomalies: A Contemporary Series. Urology, 2016, 98, 97-102.	1.0	22
62	The impact of reâ€transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 highâ€grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin. BJU International, 2016, 118, 44-52.	2.5	110
63	Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes. Urology, 2016, 94, 148-153.	1.0	33
64	Orthotopic neobladder vs. ileal conduit urinary diversion: A long-term quality-of-life comparison. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 121.e1-121.e7.	1.6	32
65	The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 239.e1-239.e8.	1.6	25
66	MP47-09 MOLECULAR CHARACTERIZATION OF SARCOMATOID CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2015, 193, .	0.4	1
67	MP59-02 IMPACT OF URETEROSCOPY PRIOR TO NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA ON ONCOLOGIC OUTCOMES. Journal of Urology, 2015, 193, .	0.4	0
68	PD11-12 URINARY TRACT INFECTION AFTER URINARY DIVERSION – DIFFERENT PATTERNS OF OCCURRENCE IN PATIENTS WITH ILEAL CONDUIT AND ORTHOTOPIC NEOBLADDER. Journal of Urology, 2015, 193, .	0.4	0
69	Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. European Urology Focus, 2015, 1, 75-81.	3.1	6
70	MP10-05 CLINICAL OUTCOME OF PATIENTS WITH FIBROSIS/NECROSIS AT POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR ADVANCED GERM CELL TUMORS. Journal of Urology, 2015, 193, .	0.4	0
71	TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Modern Pathology, 2015, 28, 845-853.	5.5	127
72	Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma. Journal of Urology, 2015, 194, 310-315.	0.4	36

#	Article	IF	Citations
73	Reply. Urology, 2015, 85, 603-604.	1.0	0
74	Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 67.e1-67.e7.	1.6	78
<b>7</b> 5	Cost Comparison of Open and Robotic Partial Nephrectomy Using a Short Postoperative Pathway. Urology, 2015, 85, 596-604.	1.0	30
76	Partial and Radical Nephrectomy for Unilateral Synchronous Multifocal Renal Cortical Tumors. Urology, 2015, 85, 1404-1410.	1.0	19
77	Subcentimeter Pulmonary Nodules are Not Associated with Disease Progression in Patients with Renal Cell Carcinoma. Journal of Urology, 2015, 193, 776-782.	0.4	18
78	Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. European Urology, 2015, 67, 74-82.	1.9	190
79	A mathematical model for predicting tumor recurrence within 24 months following surgery in patients with T1 high-grade bladder cancer treated with BCG immunotherapy. Bladder, 2015, 2, 18.	0.2	2
80	Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma. Canadian Urological Association Journal, 2014, 8, 675.	0.6	22
81	Lowâ€dose oral desmopressin for treatment of nocturia and nocturnal enuresis in patients after radical cystectomy and orthotopic urinary diversion. BJU International, 2014, 114, 727-732.	2.5	12
82	Urinary Retention in Children. Urology, 2014, 84, 1475-1479.	1.0	20
83	Open Mini-Flank Partial Nephrectomy: An Essential Contemporary Operation. Korean Journal of Urology, 2014, 55, 557.	1.2	13
84	PD18-08 CAN MUSCLEâ^INVASIVE BLADDER CANCER BE PREDICTED IN PATIENTS WITH CLINICAL T1 DISEASE?. Journal of Urology, 2014, 191, .	0.4	1
85	MP36-02 VALIDATION AND GENOMIC INTERROGATION OF THE MET VARIANT RS11762213 AS A PREDICTOR OF ADVERSE OUTCOMES IN CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2014, 191, .	0.4	0
86	Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 24-29.	0.4	15
87	MP35-19 SORBITOL AS A NOVEL MECHANISM OF HYPOXIA-INDUCIBLE FACTOR (HIF) PATHWAY ACTIVATION IN CLEAR CELL PAPILLARY RENAL CELL CARCINOMA (CCPRCC). Journal of Urology, 2014, 191, .	0.4	1
88	Urinary tract infections in patients with orthotopic neobladder. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 50.e9-50.e14.	1.6	28
89	MP23-16 <i>TCEB1</i> -MUTATED RENAL CELL CARCINOMA: A DISTINCT GENOMIC AND MORPHOLOGIC SUBTYPE. Journal of Urology, 2014, 191, .	0.4	1
90	MP23-07 REGIONAL GENETIC VARIABILITY DETECTED WITH RENAL TUMOR BIOPSIES: IMPLICATIONS IN BIOMARKER DEVELOPMENT. Journal of Urology, 2014, 191, .	0.4	1

#	Article	lF	Citations
91	MP30-18 PATHOLOGIC STAGE T3A SIGNIFICANTLY INCREASES DISEASE RECURRENCE ACROSS ALL TUMOR SIZES IN RENAL CELL CARCINOMA. Journal of Urology, 2014, 191, .	0.4	0
92	MP23-09 INTEGRATED ANALYSIS OF METASTATIC DISEASE IN CLEAR CELL RENAL CELL CARCINOMA: A COLLABORATIVE TCGA ANALYSIS. Journal of Urology, 2014, 191, .	0.4	0
93	Presence of detrusor muscle in bladder tumor specimensâ€" predictors and effect on outcome as a measure of resection quality. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 40.e17-40.e22.	1.6	28
94	PD17-07 THE CLINICAL SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN RENAL CELL CARCINOMA. Journal of Urology, 2014, 191, .	0.4	0
95	The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Medicine, 2014, 3, 1485-1492.	2.8	110
96	Testicular Torsion in the First Year of Life – Characteristics and Treatment Outcome. Urology, 2013, 82, 1132-1137.	1.0	24
97	Predictors of cancerâ€specific mortality after disease recurrence following radical cystectomy. BJU International, 2013, 111, E30-6.	2.5	77
98	440 LOW DOSE ORAL DESMOPRESSIN FOR THE TREATEMNT OF NOCTURNAL ENURESIS IN PATIENTS AFTER RADICAL CYSTECTOMY AND ORTHOTOPIC URINARY DIVERSION $\hat{a}$ $\in$ "A PROSPECTIVE CASE CONTROL STUDY. Journal of Urology, 2013, 189, .	0.4	0
99	1425 URINARY TRACT INFECTION IN PATIENTS WITH AN ORTHOTOPIC NEOBLADDER. Journal of Urology, 2013, 189, .	0.4	0
100	Treatment patterns and outcomes in "real world―patients (pts) with metastatic urothelial cancer (UC) Journal of Clinical Oncology, 2013, 31, 4525-4525.	1.6	5
101	534 RESECTION OF URETERAL ORIFICES DURING TRANSURETHRAL RESECTION OF BLADDER TUMORS - FUNCTIONAL AND ONCOLOGICAL IMPLICATIONS. Journal of Urology, 2012, 187, .	0.4	0
102	Retrograde Endoureterotomy for Persistent Ureterovesical Anastomotic Strictures in Renal Transplant Kidneys After Failed Antegrade Balloon Dilation. Urology, 2012, 80, 255-259.	1.0	31
103	Resection of Ureteral Orifice During Transurethral Resection of Bladder Tumor: Functional and Oncologic Implications. Journal of Urology, 2012, 188, 2129-2133.	0.4	22